Navigation Links
Favrille Reports Fourth Quarter and Year End 2007 Financial Results
Date:2/19/2008

p> Marketing, general

and administrative 11,198 11,170 2,400 2,945

Total operating

expenses 46,062 42,220 10,164 10,625

Interest income 1,786 2,648 363 644

Interest expense (1,053) (834) (281) (191)

Other expense (66) (105) (66) (76)

Change in valuation of

warrants 2,314 - 2,314 -

Total other income

(expense), net 2,981 1,709 2,330 377

Net loss $(43,081) $(40,511) $(7,834) $(10,248)

Historical net

loss per share:

Basic and diluted $(1.28) $(1.49) $(0.21) $(0.35)

Weighted-average

shares -

basic and

diluted 33,581,590 27,247,385 38,112,063 28,931,495

FAVRILLE, INC.

(a development stage company)

STATEMENTS OF CASH FLOWS

(in thousands)

Years ended December 31,

2007 2006

(unaudited)

Operating activities:

Net loss $(43,081) $(40,511)

Adjustments to reconcile net loss to net cash

used in operating activities:

Depreciation and amortization 3,449 2,133

Stock-based compensation 4,584 4,010

Amortization of premium/discount on short-term

investments (412) (638)

Change in valuation of warrants (2,314) -

Other
'/>"/>

SOURCE Favrille, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Favrille Announces $21.1 Million Registered Direct Offering
2. Favrille to Present at BIOCOM Investor Conference, Acumen BioFin Rodman & Renshaw Healthcare Conference and CIBC World Markets Healthcare Conference
3. Favrille to Host Conference Call and Live Webcast to Discuss Third Quarter 2007 Financial Results on October 25, 2007
4. Favrille to Present at BIO InvestorForum
5. Favrille to Present at AG Edwards Emerging Growth Conference and Wall Street Analyst Forum
6. Favrille CEO to Present at Bear Stearns Healthcare Conference
7. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
8. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
9. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
10. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
11. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. ... on providing advanced testing solutions for the detection of ... will present at the Sidoti & Company Emerging Growth ... will be held at the New York Marriott Marquis. ... will be available through the investor relations section of ...
(Date:8/26/2015)... FRANCISCO , Aug. 26, 2015  Platform ... that it has received a $1.5M Phase II ... (NIH) to further develop its therapeutic agent to ... clinical need in end stage renal disease (ESRD) ... the National Institute of Diabetes and Digestive and ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, a ... business relationships with local sponsors in southern California. The Clinical Trial Management Expert CRO ... processes and regulatory pathways., , Stem Cell Meeting on ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Nets to Prevent Serious Health Hazards ... Associated with Diethylene ... Pharmacopeial (USP),Convention today announced a revised Glycerin monograph in ... United States. The,revision strengthens safety nets to prevent serious ...
... The following was issued,today by the Greater Baltimore ... CEO, Greater Baltimore Committee, 140 company owners, executives ... The third annual Greater Baltimore Region Bioscience Awards, ... / Breakfast & Registration, 8:45 - 9:30 a.m. ...
... March 17 Mercury Therapeutics,Inc. (MTI), a ... protein,kinase targeted drugs, announces that it has ... advise on its strategic and partnering,opportunities, with ... shareholders., This appointment follows a significant ...
Cached Biology Technology:USP Announces Revised Glycerin Monograph 2USP Announces Revised Glycerin Monograph 3Greater Baltimore Committee to Announce Winners of Third Baltimore Region Bioscience Awards at Ceremonies on March 18 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 2Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities 3
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/6/2015)... CITY, Calif. , Aug. 6, 2015 /PRNewswire/ ... Valley) will visit Crossmatch ™ to learn ... networks and protect data. Crossmatch is a world ... whose technologies and expertise are helping federal agencies ... efficiency and security.   "The vast ...
(Date:8/6/2015)... SAN JOSE, Calif. , Aug. 6, 2015 ... the leading developer of human interface solutions, today ... and TouchPad technologies on Windows 10. Microsoft leveraged ... fundamental to the operating system. ... and drivers are fully certified with Microsoft,s Precision ...
Breaking Biology News(10 mins):SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Rep. Honda to Visit Crossmatch in Redwood City 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... A drug being tested to treat cancer could also ... at the University of Edinburgh found that the drug ... exacerbate symptoms associated with asthma. The findings could lead ... are resistant to steroids, which are commonly used in asthma ...
... cancer mortality in children. Even if a cure is ... treatment which can be harmful to the developing brain. ... treatment methods. The most important childhood brain tumors are ... patients each year in Germany, and pylocytic astrocytoma, which ...
... German and Portuguese . So Paulo/ ... impact on climate change than has previously been thought. The combined ... after habitat fragmentation can be up to 40 per cent less ... This is the conclusion reached by German and Brazilian researchers who ...
Cached Biology News:Germany starts its part in the International Cancer Genome Project 2Germany starts its part in the International Cancer Genome Project 3Germany starts its part in the International Cancer Genome Project 4Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 2Tropical forests affected by habitat fragmentation store less biomass and carbon dioxide 3
... for interferons are cytopathic effect inhibition assays, also ... types include; tissue culture supernatents; serum from PK ... one unit is defined as the quantity of ... effect of viral infection by 50%. ...
Request Info...
...
... is >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
Biology Products: